Patents by Inventor Robert S. Seitz

Robert S. Seitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TLE3 AS A MARKER FOR CHEMOTHERAPY
    Publication number: 20150198599
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Application
    Filed: March 27, 2015
    Publication date: July 16, 2015
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • TLE3 as a marker for chemotherapy
    Patent number: 9005900
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: April 14, 2015
    Assignee: Clarient Diagnostic Services, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • TLE3 as a marker for chemotherapy
    Patent number: 8785156
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: July 22, 2014
    Assignee: Clarient Diagnostic Services, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • Reagents and methods for use in cancer diagnosis, classification and therapy
    Patent number: 8697373
    Abstract: Methods and reagents for classifying HER2+ breast tumors and for identifying new HER2+ breast tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of HER2+ breast cancer.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: April 15, 2014
    Assignee: Clarient Diagnostic Services, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • Reagents and methods for use in cancer diagnosis, classification and therapy
    Patent number: 8440410
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: May 14, 2013
    Assignee: Clarient Diagnostic Services, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • Reagents and methods for use in cancer diagnosis, classification and therapy
    Patent number: 8399622
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: March 19, 2013
    Assignee: Clarient Diagnostic Services, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • REAGENTS AND METHODS FOR USE IN CANCER DIAGNOSIS, CLASSIFICATION AND THERAPY
    Publication number: 20120065107
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Application
    Filed: November 18, 2011
    Publication date: March 15, 2012
    Applicant: APPLIED GENOMICS, INC.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • TLE3 AS A MARKER FOR CHEMOTHERAPY
    Publication number: 20110015259
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Application
    Filed: September 24, 2010
    Publication date: January 20, 2011
    Applicant: Applied Genomics, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • REAGENTS AND METHODS FOR USE IN CANCER DIAGNOSIS, CLASSIFICATION AND THERAPY
    Publication number: 20110003709
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Application
    Filed: September 10, 2010
    Publication date: January 6, 2011
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • TLE3 as a marker for chemotherapy
    Patent number: 7816084
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: October 19, 2010
    Assignee: Applied Genomics, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • Reagents and methods for use in cancer diagnosis, classification and therapy
    Patent number: 7811774
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Grant
    Filed: January 14, 2008
    Date of Patent: October 12, 2010
    Assignee: Applied Genomics, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • TLE3 as a marker for chemotherapy
    Patent number: 7754431
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: July 13, 2010
    Assignee: Applied Genomics, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • REAGENTS AND METHODS FOR USE IN CANCER DIAGNOSIS, CLASSIFICATION AND THERAPY
    Publication number: 20100143947
    Abstract: Methods and reagents for classifying HER2+ breast tumors and for identifying new HER2+ breast tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of HER2+ breast cancer.
    Type: Application
    Filed: October 9, 2007
    Publication date: June 10, 2010
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • TLE3 AS A MARKER FOR CHEMOTHERAPY
    Publication number: 20100062444
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Application
    Filed: October 13, 2009
    Publication date: March 11, 2010
    Applicant: APPLIED GENOMICS, INC.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • TLE3 AS A MARKER FOR CHEMOTHERAPY
    Publication number: 20090155798
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Application
    Filed: November 25, 2008
    Publication date: June 18, 2009
    Applicant: APPLIED GENOMICS, INC.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • Reagents and methods for use in cancer diagnosis, classification and therapy
    Patent number: 7504225
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: March 17, 2009
    Assignees: Applied Genomics, Inc., The UAB Research Foundation
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Tyler O. Kirby, Warner Huh
  • Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
    Publication number: 20080199891
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Application
    Filed: January 14, 2008
    Publication date: August 21, 2008
    Inventors: Brian Z. Ring, douglas T. Ross, Robert S. Seitz
  • Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
    Publication number: 20080131916
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Application
    Filed: January 14, 2008
    Publication date: June 5, 2008
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • Nucleotide sequence encoding oligodendrocyte-specific protein
    Patent number: 6150136
    Abstract: A protein consisting essentially of purified oligodendrocyte-specific protein or purified biologically active variants thereof, or a combination of purified oligodendrocyte-specific protein and biologically active variants thereof. A purified and isolated peptide having the sequence Ala-Lys-Tyr-Arg-Arg-Ala-Gln-Leu-Ala-Gly, residues 115-124 of SEQ ID NO:2.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: November 21, 2000
    Assignees: The Regents of the University of California, Research Genetics, Inc.
    Inventors: Jeff M. Bronstein, Robert S. Seitz, Roger L. Lallone
  • Oligodendrocyte-specific protein
    Patent number: 6147191
    Abstract: A protein consisting essentially of purified oligodendrocyte-specific protein or purified biologically active variants thereof, or a combination of purified oligodendrocyte-specific protein and biologically active variants thereof. A purified and isolated peptide having the sequence Ala-Lys-Tyr-Arg-Arg-Ala-Gln-Leu-Ala-Gly, residues 115-124 of SEQ ID NO:2. A device for identifying an epitope region of a peptide, protein, or protein homologue of interest comprising a polypropylene membrane having a plurality of sequentially oriented peptide spots, each spot containing a peptide having an amino acid sequence where the amino acid sequences of the peptides on the peptide spots sequentially progress through the amino acid sequence of the peptide, protein, or protein homologue of interest. A method of diagnosing multiple sclerosis and a method of treating multiple sclerosis.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: November 14, 2000
    Assignee: The Regents of the University of California
    Inventors: Robert S. Seitz, Roger L. Lallone, Jeff M. Bronstein